search
Back to results

The Clinical Trial Protocol for the Inactivated Poliomyelitis Vaccine Made From Sabin Strains (IPV) (Sabin IPV)

Primary Purpose

Poliomyelitis

Status
Completed
Phase
Phase 2
Locations
China
Study Type
Interventional
Intervention
Inactivated Poliomyelitis Vaccine (Sabin strains)
Inactivated Poliomyelitis Vaccine (Sabin strains)
Inactivated Poliomyelitis Vaccine (Sabin strains)
Oral Poliomyelitis Vaccine
Inactivated Poliomyelitis Vaccine (Salk strains).
Sponsored by
Chinese Academy of Medical Sciences
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional prevention trial for Poliomyelitis focused on measuring Inactivated Poliomyelitis Vaccine, Sabin Strains, poliomyelitis

Eligibility Criteria

60 Days - 90 Days (Child)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

  • Males and females, age from 60 days to 90 days;
  • Adults, parent(s) or guardians are able to understand and sign informed consent for participation;
  • Participants or guardians are able to attend all planned clinical appointment and obey and follow all study instructions;
  • Infants no vaccinated with poliovaccine or other preventive biologicals in recent 7 days;
  • Axillary temperature ≤37℃.

Exclusion Criteria:

  • Have medical record of participants or their family on allergy, convulsion, falling sickness, encephalopathy and psychopathy;
  • Low platelet or bleeding disorder do not allow vaccination into the muscle;
  • Have damaged or lower immunological function;
  • Received blood, plasma or immunoglobulin treatment since birth;
  • Have inborn abnormality, develop obstacles or clinical diagnostic serious chronic ( Down Syndrome, diabetes, sickle cell anemia or neural Guillain-Barre Syndrome );
  • Have or be doubtful of following diseases: respiratory system diseases, acute infection or active chronic, cardiovascular diseases, liver and kidney diseases, skin diseases, HIV.

Exclusion Criteria for doses 2 and 3

  • Have serious anaphylaxis or high fever, convulsion during first dose;
  • Have any circus of Exclusion Criteria after Eligible for study;
  • Have serious adverse event which related to previous vaccination; Withdrawal and Discontinuance Criteria;
  • Received necessary or interference study drugs such as: immune-inhibition or immune-stimulating agents;
  • Vaccinated with any other vaccine(except DTP);
  • Stop observation determined by investigator owing to occurring serious adverse event;

Sites / Locations

  • Pingle Center for Disease Control and Prevention

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm 4

Arm 5

Arm Type

Experimental

Experimental

Experimental

Experimental

Experimental

Arm Label

Cohort 1: Experiment Infants

Cohort 2: Experiment infants

Cohort 3: Experiment infants

Cohort 4: Experiment infants

Cohort 5: Experiment infants

Arm Description

Biological: Inactivated Poliomyelitis Vaccine (Sabin strains) formulation A. 3x0.5ml intramuscular injections;

Biological: Inactivated Poliomyelitis Vaccine (Sabin strains) formulation B. 3x0.5ml intramuscular injections;

Biological: Inactivated Poliomyelitis Vaccine (Sabin strains) formulation C. 3x0.5ml intramuscular injections;

Biological: Oral Poliomyelitis Vaccine (OPV).3x0.1ml oral;

Biological: Inactivated Poliomyelitis Vaccine (Salk strains). 3x0.5ml intramuscular injections;

Outcomes

Primary Outcome Measures

To evaluate the safety and immunogenicity of Inactivated Poliomyelitis Vaccine made from Sabin Strains by different does on Healthy infants .

Secondary Outcome Measures

Full Information

First Posted
January 25, 2010
Last Updated
July 31, 2016
Sponsor
Chinese Academy of Medical Sciences
Collaborators
Guangxi Center for Disease Control and Prevention, National Institute for the Control of Pharmaceutical and Biological Products, China
search

1. Study Identification

Unique Protocol Identification Number
NCT01056705
Brief Title
The Clinical Trial Protocol for the Inactivated Poliomyelitis Vaccine Made From Sabin Strains (IPV)
Acronym
Sabin IPV
Official Title
The Phase Ⅱ Clinical Trial Protocol for the Inactivated Poliomyelitis Vaccine Made From Sabin Strains
Study Type
Interventional

2. Study Status

Record Verification Date
July 2016
Overall Recruitment Status
Completed
Study Start Date
July 2009 (undefined)
Primary Completion Date
May 2010 (Actual)
Study Completion Date
August 2010 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Chinese Academy of Medical Sciences
Collaborators
Guangxi Center for Disease Control and Prevention, National Institute for the Control of Pharmaceutical and Biological Products, China

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
Based on pre-clinical trial and phase 1 clinical data and principle of GCP, the objective of phase Ⅱ clinical trial is to evaluate safety and immunogenicity of Inactivated Poliomyelitis Vaccine made from Sabin Strains(Sabin IPV).
Detailed Description
The Sabin IPV was manufactured with poliovirus type1, 2, 3 Sabin strains and Vero cells by microcarrier culture in 550 liter bioreactors. The virus suspension was harvested ,ultra-concentrated, purified and inactivated with formalin. Three formulations A,B,C of Sabin IPV were used, the DAg contents for A were type1 45,type2 64,type3 67.5 DU /0.5ml/per dose; for B 30,32,45 DU/0.5ml/per dose; for C 15,16,22.5 DU/0.5ml/per dose. Oral Poliomyelitis Vaccine(OPV)was manufactured by Institute of Medical Biology, Chinese Academy of Medical Sciences.Trivalent OPV contains Polioviruses Type 1 6.0 log CCID Type 2 5.0 log Type 3 5.5log /0.1ml/per dose Inactivated Poliomyelitis Vaccine (Salk strains)was manufactured by Sanofi Pasteur DAg contents /0.5ml/per dose were Type 1 40 DU,Type 2 8DU,Type 3 32DU. This is a randomized, blind phase 2 clinical trial. Total 500 infants (ages 60 days to 90 days) were selected , randomized to five groups(each group n=100) Sabin IPV formulations A,B,C,OPV ,Salk IPV were separately given to each group with three doses one month apart respectively.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Poliomyelitis
Keywords
Inactivated Poliomyelitis Vaccine, Sabin Strains, poliomyelitis

7. Study Design

Primary Purpose
Prevention
Study Phase
Phase 2
Interventional Study Model
Parallel Assignment
Masking
Outcomes Assessor
Allocation
Randomized
Enrollment
500 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Cohort 1: Experiment Infants
Arm Type
Experimental
Arm Description
Biological: Inactivated Poliomyelitis Vaccine (Sabin strains) formulation A. 3x0.5ml intramuscular injections;
Arm Title
Cohort 2: Experiment infants
Arm Type
Experimental
Arm Description
Biological: Inactivated Poliomyelitis Vaccine (Sabin strains) formulation B. 3x0.5ml intramuscular injections;
Arm Title
Cohort 3: Experiment infants
Arm Type
Experimental
Arm Description
Biological: Inactivated Poliomyelitis Vaccine (Sabin strains) formulation C. 3x0.5ml intramuscular injections;
Arm Title
Cohort 4: Experiment infants
Arm Type
Experimental
Arm Description
Biological: Oral Poliomyelitis Vaccine (OPV).3x0.1ml oral;
Arm Title
Cohort 5: Experiment infants
Arm Type
Experimental
Arm Description
Biological: Inactivated Poliomyelitis Vaccine (Salk strains). 3x0.5ml intramuscular injections;
Intervention Type
Biological
Intervention Name(s)
Inactivated Poliomyelitis Vaccine (Sabin strains)
Other Intervention Name(s)
Sabin IPV
Intervention Description
Inactivated Poliomyelitis Vaccine (Sabin strains) formulation A. 3x0.5ml intramuscular injections,one month apart.
Intervention Type
Biological
Intervention Name(s)
Inactivated Poliomyelitis Vaccine (Sabin strains)
Other Intervention Name(s)
Sabin IPV
Intervention Description
Inactivated Poliomyelitis Vaccine (Sabin strains) formulation B. 3x0.5ml intramuscular injections, one month apart.
Intervention Type
Biological
Intervention Name(s)
Inactivated Poliomyelitis Vaccine (Sabin strains)
Other Intervention Name(s)
Sabin IPV
Intervention Description
Inactivated Poliomyelitis Vaccine (Sabin strains) formulation C. 3x0.5ml intramuscular injections, one month apart.
Intervention Type
Biological
Intervention Name(s)
Oral Poliomyelitis Vaccine
Other Intervention Name(s)
OPV
Intervention Description
Oral Poliomyelitis Vaccine (OPV).3x0.5mloral, one month apart.
Intervention Type
Biological
Intervention Name(s)
Inactivated Poliomyelitis Vaccine (Salk strains).
Other Intervention Name(s)
Salk IPV
Intervention Description
3x0.5ml intramuscular injections, one month apart.
Primary Outcome Measure Information:
Title
To evaluate the safety and immunogenicity of Inactivated Poliomyelitis Vaccine made from Sabin Strains by different does on Healthy infants .
Time Frame
one year

10. Eligibility

Sex
All
Minimum Age & Unit of Time
60 Days
Maximum Age & Unit of Time
90 Days
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Males and females, age from 60 days to 90 days; Adults, parent(s) or guardians are able to understand and sign informed consent for participation; Participants or guardians are able to attend all planned clinical appointment and obey and follow all study instructions; Infants no vaccinated with poliovaccine or other preventive biologicals in recent 7 days; Axillary temperature ≤37℃. Exclusion Criteria: Have medical record of participants or their family on allergy, convulsion, falling sickness, encephalopathy and psychopathy; Low platelet or bleeding disorder do not allow vaccination into the muscle; Have damaged or lower immunological function; Received blood, plasma or immunoglobulin treatment since birth; Have inborn abnormality, develop obstacles or clinical diagnostic serious chronic ( Down Syndrome, diabetes, sickle cell anemia or neural Guillain-Barre Syndrome ); Have or be doubtful of following diseases: respiratory system diseases, acute infection or active chronic, cardiovascular diseases, liver and kidney diseases, skin diseases, HIV. Exclusion Criteria for doses 2 and 3 Have serious anaphylaxis or high fever, convulsion during first dose; Have any circus of Exclusion Criteria after Eligible for study; Have serious adverse event which related to previous vaccination; Withdrawal and Discontinuance Criteria; Received necessary or interference study drugs such as: immune-inhibition or immune-stimulating agents; Vaccinated with any other vaccine(except DTP); Stop observation determined by investigator owing to occurring serious adverse event;
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Liao Guoyang, PHD
Organizational Affiliation
Institute of Medical Biology, Chinese Academy of Medical Sciences
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Li Rongcheng, MD
Organizational Affiliation
Guangxi Zhuang Autonomous Region Center for Disease Prevention and Control
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Li Changgui, PHD
Organizational Affiliation
National Institute for the Control of Pharmaceutical and Biological Products, China
Official's Role
Principal Investigator
Facility Information:
Facility Name
Pingle Center for Disease Control and Prevention
City
Pingle county
State/Province
Guangxi
ZIP/Postal Code
542400
Country
China

12. IPD Sharing Statement

Citations:
PubMed Identifier
28419204
Citation
Sun M, Li C, Xu W, Liao G, Li R, Zhou J, Li Y, Cai W, Yan D, Che Y, Ying Z, Wang J, Yang H, Ma Y, Ma L, Ji G, Shi L, Jiang S, Li Q. Immune Serum From Sabin Inactivated Poliovirus Vaccine Immunization Neutralizes Multiple Individual Wild and Vaccine-Derived Polioviruses. Clin Infect Dis. 2017 May 15;64(10):1317-1325. doi: 10.1093/cid/cix110. Erratum In: Clin Infect Dis. 2017 Oct 15;65(8):1431-1433.
Results Reference
derived
PubMed Identifier
22158682
Citation
Liao G, Li R, Li C, Sun M, Li Y, Chu J, Jiang S, Li Q. Safety and immunogenicity of inactivated poliovirus vaccine made from Sabin strains: a phase II, randomized, positive-controlled trial. J Infect Dis. 2012 Jan 15;205(2):237-43. doi: 10.1093/infdis/jir723. Epub 2011 Dec 8.
Results Reference
derived
Links:
URL
http://imbcams.ac.cn/Index.html
Description
Home page of Institute of Medical Biology, Chinese Academy of Medical Sciences

Learn more about this trial

The Clinical Trial Protocol for the Inactivated Poliomyelitis Vaccine Made From Sabin Strains (IPV)

We'll reach out to this number within 24 hrs